期刊
CANCER LETTERS
卷 348, 期 1-2, 页码 156-166出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.canlet.2014.03.016
关键词
TRAIL; Pancreatic cancer; Triptolide; Apoptosis; Death receptor
类别
资金
- Masonic Cancer Center, the Department of Surgery, Pancreatic Cancer SPORE grant to the University of Minnesota and University of Alabama
- Katherine and Robert Goodale Foundation
- Hirshberg Foundation
- National Institute of Health [R01CA124723, R01 CA170496]
The tumor necrosis factor related apoptosis-inducing ligand (TRAIL) causes cancer cell death, but many cancers, including pancreatic cancer, are resistant to TRAIL therapy. A combination of TRAIL and the diterpene triepoxide, triptolide, is effective in inducing pancreatic cancer cell death. Triptolide increases levels of death receptor DR5 and decreases the pro-survival FLICE-like inhibitory protein (c-FLIP), which contribute to the activation of caspase-8. This combination further causes both lysosomal and mitochondrial membrane permeabilization, resulting in cell death. Our study provides a mechanism by which triptolide sensitizes TRAIL resistant cells, which may become a novel therapeutic strategy against pancreatic cancer. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据